Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, completed the acquisition of Synaffix, a biotechnology company, for €160m. "On our mission to bring Synaffix’s ADC technologies to patients, we are excited to become part of Lonza and thus, through strong and immediate synergies, ensure a robust technology and manufacturing platform for our licensees as they progress into the late stage clinical and commercial development phase. We can now also leverage the potential offered by Lonza to fast-track technology innovations in bioconjugates beyond cytotoxic ADCs. We look forward to working closely with our colleagues at Lonza for the continued enablement of promising potential medicines for patients in need," Peter van de Sande, Synaffix CEO.